Voyageur Pharmaceuticals Announces Collaboration with Bayer

The most recent news (February 23, 2026) announces a collaboration and funding agreement with global pharmaceutical giant Bayer. The agreement provides milestone-based funding of up to USD$2.35 million to evaluate iodine extraction in Oklahoma. Key financial milestones include an immediate USD$350,000 payment, USD$1 million upon starting a feasibility study, and USD$1 million upon its completion. In exchange, Bayer receives an exclusivity period to negotiate an offtake agreement for the resulting iodine production. Voyageur retains 100% ownership of all developed intellectual property.

This news is Material - Positive for several reasons: - Validation: Engagement with a Tier-1 global player like Bayer provides significant third-party validation of Voyageur’s "Earth to Bottle" business model. - Non-Dilutive Capital: The USD$2.35 million (approx. CAD$3.2M) is non-dilutive, which is critical for a company that had only CAD$943,155 in cash as of August 2025 and a history of high burn rates. - Strategic Shift: This confirms the company's pivot toward the Oklahoma iodine project as a major value driver alongside its Frances Creek barium project. - IP Protection: Retaining 100% of the IP while receiving external funding is a highly favorable term for a micro-cap company.

Voyageur aims to be the first vertically integrated "Earth to Bottle" radiology drug company in North America. - Flagship Project 1: Frances Creek (BC, Canada) - High-grade barium sulphate (barite) with a $344M NPV (2022 PEA). - Flagship Project 2: Oklahoma Iodine - Focused on extracting iodine from oilfield brines to bypass expensive foreign supply chains. - Product Line: Five Health Canada-licensed barium contrast products (Smooth and Vision lines).